Sopernis Pharmaceuticals (SUPN) Q1 2026: Growth Products Surge 56% as Adult ADHD Prescribers Overtake Pediatrics
Sopernis Pharmaceuticals’ Q1 2026 results showcase a decisive pivot to growth products, with adult ADHD and CNS franchises driving operational momentum. The quarter marked a rebound in Onapco following supply constraints, robust expansion in Zerzuve and Kelby, and disciplined execution on pipeline and M&A priorities. Management’s tone and guidance reinforce confidence in continued outperformance, but product-specific conversion and supply chain risks remain material watchpoints for investors.
Summary
- Adult ADHD Franchise Expands: Kelby’s adult prescriptions outpaced pediatrics for the first time, broadening market penetration.
- Supply Chain Stability Returns: Onapco’s patient initiations rebounded, with March metrics exceeding pre-constraint levels.
- Growth Platform Focus: Management prioritizes revenue-generating CNS and women’s health assets for future M&A.
Business Overview
Sopernis Pharmaceuticals is a specialty biopharmaceutical company focused on central nervous system (CNS) disorders and women’s health. The company generates revenue from a portfolio of commercial products—primarily Kelby (ADHD), GoCovery (opioid addiction), Onapco (Parkinson’s disease), and Zerzuve (postpartum depression)—as well as through collaboration, royalty, and licensing agreements. Its major segments include commercial product sales, collaboration revenues (notably with Biogen and Viagin), and pipeline development in CNS therapeutics.
Performance Analysis
Q1 2026 marked a 39% year-over-year increase in total revenue, underpinned by a 56% surge in growth product sales and strong collaboration revenue from Zerzuve and licensing milestones. Commercial product revenues increased 26% versus prior year, led by Kelby (ADHD) and GoCovery (opioid addiction), while Zerzuve collaboration revenue doubled, reflecting accelerating market uptake.
Kelby’s momentum was especially notable: adult prescription growth of 27% outstripped pediatric growth (15%), and total adult prescribers surpassed pediatrics for the first time. Onapco rebounded from supply constraints, with March prescription and prescriber metrics exceeding pre-disruption levels. Management highlighted a backlog of 570 Onapco patients in the queue, and conversion rates remain a key determinant for 2026 guidance realization. Operating loss narrowed on higher revenues, though SG&A rose due to collaboration-related spend. The company exited the quarter with $384 million in cash and no debt, enhancing financial flexibility for M&A.
- Collaboration Revenue Inflection: Zerzuve’s US sales doubled year-over-year, with 82% growth in prescriptions and 73% growth in prescribers, signaling durable demand.
- Kelby’s Adult Franchise Surpasses Pediatrics: For the first time, adult prescribers outnumbered pediatric, reflecting effective resource reallocation and market expansion.
- Operating Leverage Emerges: Despite higher SG&A, adjusted operating earnings rose 11% year-over-year, supporting Sopernis’ deleveraging narrative.
Growth product outperformance and collaboration milestones offset increased SG&A, but investor focus remains on Onapco’s conversion rates and supply chain execution as key levers for hitting the upper end of 2026 guidance.
Executive Commentary
"We are pleased with the rebound in the business since we resumed patient initiations with some of the metrics in March reaching or even exceeding levels achieved before the supply constraints."
Jack Picar, Chief Executive Officer
"The company's balance sheet remains strong with no debt and significant financial flexibility for potential M&A and other growth opportunities."
Tim Dannen, Chief Financial Officer
Strategic Positioning
1. Growth Product Leadership in CNS and ADHD
Sopernis’ strategic focus on CNS and ADHD markets is yielding tangible results, as Kelby’s adult market penetration accelerates and GoCovery maintains double-digit growth. The company’s ability to broaden Kelby’s patient profile—from stimulant-intolerant to complex ADHD—demonstrates its evolving value proposition and market adaptability.
2. Supply Chain Resilience and Scalability
Onapco’s rebound after supply constraints validates Sopernis’ operational agility, but future growth depends on timely FDA approval of a second supplier. Management’s pursuit of multiple suppliers, including a potential third, signals a proactive approach to de-risking manufacturing and scaling for anticipated demand in 2027 and beyond.
3. Pipeline and M&A Discipline
R&D investment remains focused on late-stage CNS opportunities, including SPN820 (major depressive disorder) and SPN817 (treatment-resistant seizures), with a phase one ADHD candidate (SBN443) entering clinical development in late 2026. Management’s M&A appetite is centered on wholly owned, revenue-generating assets in CNS and women’s health, reinforcing a disciplined, growth-oriented capital allocation strategy.
Key Considerations
This quarter’s results reinforce Sopernis’ transition from legacy to growth, but execution on conversion rates, supply chain, and pipeline timelines will determine if outperformance is sustainable.
Key Considerations:
- Conversion Rate Watch: Onapco’s guidance depends on converting a high percentage of patient start forms to paying patients, with current drop-off rates around 40-45%.
- Adult ADHD Opportunity: Kelby is capturing adult market share, with once-daily dosing and all-day coverage differentiating it from stimulants.
- Collaboration Upside: Zerzuve’s early innings adoption and DTC campaigns can unlock a large, underpenetrated postpartum depression market.
- Balance Sheet Flexibility: Cash reserves and no debt position Sopernis for opportunistic M&A or pipeline acceleration.
Risks
Onapco’s commercial trajectory is exposed to patient conversion bottlenecks and regulatory timing for second supplier approval, with any delay potentially capping revenue growth. Broader risks include competitive encroachment in CNS and ADHD, payer dynamics, and execution risk on late-stage pipeline assets. Management’s focus on supply chain redundancy and market education helps mitigate, but not eliminate, these uncertainties.
Forward Outlook
For Q2 2026, Sopernis expects continued growth in commercial product revenues and momentum in Onapco patient initiations.
- Total revenue guidance for 2026: $840 million to $870 million
- Combined R&D and SG&A expense: $620 million to $650 million
For full-year 2026, management reiterated guidance:
- Non-GAAP operating earnings: $140 million to $170 million
Management cited continued strength in growth products, further progress on supply chain redundancy, and disciplined capital allocation as key drivers for the remainder of the year.
- Onapco conversion rates and backlog throughput will be critical watchpoints
- Kelby’s adult market expansion and Zerzuve DTC campaign traction are expected to drive incremental upside
Takeaways
Sopernis’ Q1 2026 results highlight a company in transition, with growth products and adult ADHD franchise now at the forefront. Supply chain stabilization and a robust balance sheet underpin management’s confidence, but execution on patient conversion and regulatory milestones remain key to sustaining momentum.
- Growth Product Acceleration: Kelby and Zerzuve are emerging as durable growth engines, with new patient segments and expanded prescriber bases fueling topline upside.
- Operational Discipline: Supply chain and conversion process improvements are mitigating past disruptions, but vigilance is warranted as backlog and regulatory timelines remain fluid.
- Pipeline and M&A Optionality: Ample cash and a focused acquisition strategy provide levers for future growth, but investors should monitor execution on both organic and inorganic fronts.
Conclusion
Sopernis Pharmaceuticals delivered a strong Q1 2026, propelled by growth product outperformance and strategic focus on adult ADHD and CNS markets. While operational and regulatory risks persist, the company’s financial flexibility and disciplined execution position it well for continued leadership in its core therapeutic areas.
Industry Read-Through
Sopernis’ results signal accelerating momentum for specialty CNS and women’s health franchises, with adult ADHD emerging as a major growth vector industry-wide. The successful rebound from supply chain disruption underscores the importance of manufacturing redundancy for all specialty pharma players. Rising SG&A tied to collaboration and DTC investments reflects a broader trend of companies seeking to expand market education and prescriber reach in underpenetrated segments. Competitors in CNS, ADHD, and women’s health should expect intensified focus on adult patient populations, innovative dosing regimens, and direct-to-consumer marketing as key levers for future share gains.